How to set up a global biopharma intelligence pipeline in 30 minutes

Most BD teams we talk to spend 90 minutes a morning reading news to do a job that should take 5 minutes. Sometimes more, often less, but the pattern is the same: an hour of tab-switching between FDA · NMPA · ClinicalTrials · FierceBiotech · SEC EDGAR · HKEX · ICH · PMDA and your favorite paid biopharma newsletter.

A daily intelligence pipeline can replace all of that with a 5-minute brief — IF you set it up right. This post is the 30-minute version of that setup, with the build-vs-buy decisions called out.

What you actually need

The pipeline has five stages. In order:

1. Crawl — pull from N+ sources hourly
2. Parse — turn HTML / PDFs into structured text
3. Extract — identify the entities (companies, drugs, targets, indications, phases)
4. Align — dedupe and cross-reference the same event across sources
5. Distribute — push tiered summaries to where you work

Skip stage 4 and you will get the same FDA approval in 6 different sources every morning. Skip stage 3 and you cannot filter by "ADC programs at Phase 3." Skip stage 1 and you are reading whatever Twitter algorithm decided to show you.

Stage 1 — Crawl

The 7 sources we recommend as a baseline:

• PubMed — APIs are mature (NCBI Entrez)
• ClinicalTrials.gov — APIs are also mature
• FDA — RSS feeds for approvals, recalls, guidance
• NMPA — HTML scraping; respect rate limits
• EMA — APIs + RSS
• FierceBiotech — RSS (the most-cited industry newsletter)
• SEC EDGAR — APIs for biotech filings

Open-source tools that work today: Crawl4AI for intelligent scraping, Playwright for JS-heavy sources, Scrapy for structured ones.

Time budget: 10 minutes for the well-documented APIs (PubMed, ClinicalTrials, FDA, EMA, SEC). 1 hour for NMPA scraping if you are doing it yourself. 5 minutes if you just use the InBeacon connector.

Stage 2 — Parse

PDF parsing is where most pipelines bog down. FDA guidance documents are PDFs. NMPA review documents are PDFs. Many EU and Asian regulatory docs are PDFs. They are structurally inconsistent.

The honest open-source tools:

• MinerU — best for Chinese PDFs and tables
• Docling — best for English structured PDFs
• GROBID — best for academic papers with metadata
• PaperQA2's pipeline — best for full-text scientific articles

You will end up needing two or three because no single tool handles regulatory + scientific + tabular content uniformly well.

Stage 3 — Extract

Named entity recognition for biopharma is its own discipline. Companies are easy. Targets are harder (HER2 vs ERBB2 vs HER-2 — same target). Drugs are the worst (international non-proprietary names, brand names, codes, all referring to the same molecule).

What works today:

• GLiNER — generic open-source NER, works well for companies
• Custom NER models — needed for targets and drugs
• LLM fallback — for the long tail (Gemini, Claude, GPT-4 all work for entity disambiguation when given context)

The honest cost: stage 3 is the most expensive in CPU and most expensive in eng time. Budget more here than anywhere else if building from scratch.

Stage 4 — Cross-source align

The single most underrated stage. Without it, your morning brief has the FDA approval of tobinetamab 6 times — once each from FDA, SEC EDGAR (the sponsor's 8-K), FierceBiotech, the company's press release, your favorite stock news source, and a follow-up analyst note.

Cross-source alignment requires:

• An entity resolution layer (the 6 mentions of tobinetamab map to the same molecule)
• A temporal alignment layer (the event happened on date X, the 6 mentions are reactions)
• A deduplication policy (which mention is "primary")

This is the largest engineering investment in a do-it-yourself pipeline. It is also the difference between a daily brief that is readable and a daily brief that is noise.

Stage 5 — Distribute

Once you have aligned events, you have three options:

• Email digest — easiest. SMTP server + simple templating.
• Slack / WeChat / DingTalk webhook — most engaging. Each platform has well-documented webhook APIs.
• In-app feed — most engaging-but-also-most-engineering.

Whichever you pick, the trick is tiered summaries: 1-line headline → 3-sentence summary → full brief. Different people want different levels.

The build-vs-buy honest answer

If you are a 3-person BD team at a 30-person biotech, build none of this. Use a service. We made InBeacon because we did this build for ourselves and realized the time-to-value calculus does not favor in-house.

If you are a top-20 pharma with a dedicated data engineering team, build stage 1-2 yourself (you want control) and buy stage 3-5 (you do not want to maintain entity resolution models).

If you are a CRO, you almost certainly need this for your sponsors. Buy or build — but stop trying to do it through a person reading Twitter.

The 30-minute version

The "30 minutes" claim in this post's title is honest for one path: you sign up for an existing service, you pick your 5 watchlist topics, you point the webhook at your Slack. Done.

If you are building from scratch, it is more like 30 person-days, not 30 minutes. The technology has matured to the point where building is feasible; the question is whether building is the best use of your time.

The brief still gets you out of 90 minutes of tab-switching either way.